Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,060.86 USD
+5.29 (0.50%)
Updated Jul 24, 2024 04:00 PM ET
Pre-Market: $1,065.30 +4.44 (0.42%) 9:12 AM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1,060.86 USD
+5.29 (0.50%)
Updated Jul 24, 2024 04:00 PM ET
Pre-Market: $1,065.30 +4.44 (0.42%) 9:12 AM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
Zacks News
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Here's Why You Should Add Alnylam (ALNY) Stock to Your Portfolio
by Zacks Equity Research
Alnylam's (ALNY) revenues continue to be driven by Amvuttra and Givlaari sales. Its existing collaboration agreement with Regeneron to develop RNAi-based candidates is progressing well.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
What's in Store for Thermo Fisher (TMO) in Q2 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) is likely to have generated growth in the second quarter, driven by a favorable business mix and new launches.
Alnylam (ALNY) Posts Upbeat Data From Alzheimer's Disease Study
by Zacks Equity Research
Alnylam (ALNY) announces positive interim analysis data from the Part A of its early-stage study of ALN-APP in the treatment of early-onset Alzheimer's disease and cerebral amyloid angiopathy.
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
UnitedHealth Group (UNH) Q2 Earnings Beat, Boosts '23 EPS View
by Zacks Equity Research
UnitedHealth Group's (UNH) Q2 results benefited on the back of solid contributions from the UnitedHealthcare and Optum segments. Management presently forecasts adjusted net EPS within $24.70-$25.00 for 2023.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Regeneron (REGN) Loses 13% in Three Months: What Lies Ahead?
by Zacks Equity Research
Regeneron (REGN) declines 13% in the last three months due to regulatory setback for 8 mg dose strength of aflibercept and competition for lead drug.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Catalent's (CTLT) Facility Snag Linked to Regeneron's Eylea CRL
by Zacks Equity Research
Catalent's (CTLT) drug manufacturing facility in Indiana faces problems, which is linked to FDA's rejection of Regeneron's eye drug application. This is the latest in a string of quality control issues for Catalent.
The Zacks Analyst Blog Highlights Texas Instruments, Regeneron Pharmaceuticals, Micron Technology, FedEx and Arista Networks
by Zacks Equity Research
Texas Instruments, Regeneron Pharmaceuticals, Micron Technology, FedEx and Arista Networks are included in this Analyst Blog.
Sanofi (SNY) Atopic Dermatitis Drug Meets Goals in Phase II Study
by Zacks Equity Research
Sanofi's (SNY) phase II study, investigating amlitelimab for moderate-to-severe atopic dermatitis in adults, meets the primary endpoint.
Top Analyst Reports for Texas Instruments, Regeneron & Micron Technology
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments Inc. (TXN), Regeneron Pharmaceuticals, Inc. (REGN) and Micron Technology, Inc. (MU).
Regeneron (REGN) Gets CRL for Aflibercept 8 mg Drug, Shares Fall
by Zacks Equity Research
Regeneron (REGN) receives a completed response letter for the application seeking approval of aflibercept 8 mg for treating several retinopathic indications. The stock falls 9% following the news.
Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Regeneron (REGN) closed at $771.11 in the latest trading session, marking a +0.49% move from the prior day.
Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Regeneron (REGN) closed at $750.12, marking a +1.56% move from the previous day.
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Is First Trust NASDAQ-100 Equal Weighted ETF (QQEW) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for QQEW
Kodiak (KOD) Advances With Tarcocimab Amid Stiff Competition
by Zacks Equity Research
Kodiak (KOD) focuses on completing ongoing studies on tarcocimab for several retinal indications. However, competition in the market and the lack of other candidates in the pipeline are concerns.
Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study
by Zacks Equity Research
A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Alimera (ALIM) Completes Enrollment in Eye Disease Study
by Zacks Equity Research
Alimera (ALIM) announces completion of patient enrollment in its NEW DAY study to evaluate Iluvien 0.19 mg as a baseline therapy in diabetic macular edema. The stock surges 8% on Wednesday.
The Zacks Analyst Blog Highlights AbbVie, Intel, Qualcomm, Regeneron and CME Group
by Zacks Equity Research
AbbVie, Intel, Qualcomm, Regeneron and CME Group are included in this Analyst Blog.
Top Research Reports for AbbVie, Intel & Qualcomm
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Intel Corporation (INTC) and Qualcomm Inc. (QCOM).